文献検索式

MEDLINE(Dialog)
PubMed

Ⅰ.対象データ:2007 年7 月1 日〜2011 年12 月31 日

疾患:肝細胞癌に限定(動物実験を除く)
言語:英語・日本語文献に限定
※新設されたCQ については,1982 年1 月1 日〜2011 年12 月31 日で検索

Ⅱ.検索式

【第1章 予 防】
CQ1 インターフェロンは,C 型慢性肝疾患からの発癌予防に有効か?[PubMed]

#1

“Liver Neoplasms”[MH]AND“Interferons”[majr]AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Liver Neoplasms”[MH]AND“Interferons”[majr]AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ2 肝庇護療法は肝細胞癌の発癌予防に有効か?[PubMed]

#1

“Carcinoma, Hepatocellular/prevention and control”[MH]AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Carcinoma, Hepatocellular/prevention and control”[MH]AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ3 B型慢性肝疾患に対する抗ウイルス療法は肝細胞癌の発癌予防に有効か?[PubMed]

#1

“Liver Neoplasms”[MH]AND(“lamivudine”[tiab]OR“adefovir dipivoxil”[Supplementary Concept]OR adefovir[tiab]OR“tenofovir disoproxil”[Supplementary Concept]OR tenofovir[tiab]OR“entecavir”[Supplementary Concept]OR entecavir[tiab]OR 3TC[tiab]OR emtricitabine[Supplementary Concept]OR emtricitabine[tiab])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Liver Neoplasms”[MH]AND(“lamivudine”[tiab]OR“adefovir dipivoxil”[Supplementary Concept]OR adefovir[tiab]OR“tenofovir disoproxil”[Supplementary Concept]OR tenofovir[tiab]OR“entecavir”[Supplementary Concept]OR entecavir[tiab]OR 3TC[tiab]OR emtricitabine[Supplementary Concept]OR emtricitabine[tiab])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

【第2章 診断およびサーベイランス】
CQ4 サーベイランスは,どのような対象に行うか?[PubMed]

#1

“Risk Factors”[MH]“Carcinoma, Hepatocellular”[majr]AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Risk Factors”[MH]“Carcinoma, Hepatocellular”[majr]AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ5 サーベイランスは,予後を改善するか?[PubMed]
CQ6 サーベイランスは,どのような方法で行うか?[PubMed]

#1

“Liver Neoplasms”[MH]AND(surveillance[tiab]OR screening[tiab])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Liver Neoplasms”[MH]AND(surveillance[tiab]OR screening[tiab])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ7

Dynamic CT/MRIで典型的所見を示さない肝結節の精査は,何cm以上から行うのが望ましいか?
[PubMed]

#1

“Liver Neoplasms”[MH]AND(biopsy[MH]OR hepatectomy[MH]OR pathology[MH]OR patholo*[tiab]OR resection*[tiab])AND(“MRI”[tiab]OR“CT”[tiab]OR ultraso*[tiab])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Liver Neoplasms”[MH]AND(biopsy[MH]OR hepatectomy[MH]OR pathology[MH]OR patholo*[tiab]OR resection*[tiab])AND(“MRI”[tiab]OR“CT”[tiab]OR ultraso*[tiab])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ8 肝細胞癌の診断において2種以上の腫瘍マーカーを測定することは有用か?[PubMed]

#1

“Liver Neoplasms”[MH]AND“sensitivity and specificity”[MH]AND(“AFP”[tiab]OR“alphaf*”[tiab]OR“DCP”[tiab]OR des―gamma*[tiab]OR desgamma*[tiab]OR PIVKA*[tiab]OR Glypican―3[tiab]OR GP3[tiab]OR“Tumor Markers, Biological”[MH])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

“Liver Neoplasms”[MH]AND“sensitivity and specificity”[MH]AND(“AFP”[tiab]OR alphaf*[tiab]OR“DCP”[tiab]OR des―gamma*[tiab]OR desgamma*[tiab]OR PIVKA*[tiab]OR Glypican―3[tiab]OR GP3[tiab]OR“Tumor Markers, Biological”[MH])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ9 腫瘍マーカーの測定は,肝細胞癌の治療後の指標として有効か?[PubMed]

#1

“Liver Neoplasms/therapy”[majr]AND(“AFP”[tiab]OR alphaf*[tiab]OR“DCP”[tiab]OR des―gamma*[tiab]OR desgamma*[tiab]OR PIVKA*[tiab]OR“Tumor Markers, Biological”[MH])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

Liver Neoplasms/therapy”[majr]AND(“AFP”[tiab]OR alphaf*[tiab]OR“DCP”[tiab]OR des―gamma*[tiab]OR desgamma*[tiab]OR PIVKA*[tiab]OR“Tumor Markers, Biological”[MH])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ10 肝硬変患者における早期肝細胞癌の検出において,診断能が高い検査は何か?[MEDLINE]

S1

LIVER CIRRHOSIS! OR(LIVER OR LIVERS OR HEPATIC)(3N)CIRRHO? OR CHRONIC?(3N)LIVER(2W)(DISEASE? OR DISORDER?)

S2

(WELL()DIFFERENTI? OR SMALL? OR HYPOVASCULAR? OR ADENOMATOUS?(3N)HYPERPLASI? OR DYSPLASTI?(3N)NODUL?)/TI

S3

(BORDERLIN? OR NODUL?)/TI

S4

INTERNATIONAL?(3N)CONSENS?(3N)GROUP?(3N)HEPATOCEL?()NEOPLAS?

S5

FOCAL NODULAR HYPERPLASIA!

S6

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S7

EARLY(4N)(CARCINOM? OR HCC OR HEPATOM? OR NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR HAEPATOM? OR HCCS)

S8

DISEASE PROGRESSION!

S9

DI/DE OR US/DE OR RA/DE OR RI/DE OR DIAGNOSTIC IMAGING!

S10

CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING?

S11

OUTCOME?/TI

S12

SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC

S13

(S1/DE OR S1/TI OR S2 OR S3 OR S4 OR S5)*(S6+S7+S8)*(S9+S10)

S14

S13*(LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND S11

S15

(DIAGNOS? OR IDENTI? OR DETECT? OR ASSESS? OR EVALUAT? OR MANAGE?)/TI

S16

(LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?)/TI AND S13 AND(S15+S10/TI)

S17

S16*S12

S18

S17+S14

S19

S18/HUMAN+(S18 NOT ANIMALS)

S20

S19/ENG

S21

S20 AND PY=>1982 AND UP=19830906:20111231

●CQ11 肝細胞癌の高危険群において,典型的肝細胞癌の診断に診断能が高い検査は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

(DI+DIAGNOSIS!+RA+RI+US)/DF+(DIAGNOS? OR DETECT? OR IDENTI?OR TEST? OR IMAG?)/TI

S6

SENSITIVIT?+SPECIFICIT?+ACCURAC?

S7

S4*S5*S6

S8

(USEFUL? OR EFFICAC? OR EFFECTIV?)/TI

S9

MT/DE

S10

S7*S8*S9

S11

S7*S8+S7*S9

CQ12 肝細胞癌の治療前検査として血管造影は必要か?[MEDLINE]
CQ13 肝細胞癌の治療前検査としてCTAP/CTHAは必要か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14 AND UP=20070701:20111231

S16

PREEXAMINAT?+PRE(1W)EXAMINAT?+PREDIAGNOS?+PRETREATMENT?+PRETHERAP?+PRE(1W)(DIAGNO?+TREATMENT?+THERAP?)

S17

ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+CTHA+CTAP+CT/AB+CT/TI+TOMOGRA?+MDCT+NMR+MRI+SPECT+PET

S18

S15*S16*S17

S19

S15*S12/TI*S17/TI

S20

S18+S19

CQ14 腎機能および肝機能低下患者における肝腫瘍の診断には,どの検査法が有用か?[MEDLINE]

S1

(LIVER+HEPATIC?+HEPATO?+KIDNEY+RENAL+CK+CREATIN?)(3N)(FUNCTION?+IMPAIR?+FAILUR?+INSUFFICIEN?+DETERIORA?+EXACERBAT?+DYSFUNCT?+HYPOFUNCT?+LESION?+DISORDER?+DAMAGE?+ABNORMAL?)

S2

NEPHROPATH? OR CIRRHO? OR NEPHRITI?

S3

JAUNDIC? OR HYPERBIL? OR(BIL OR BILI?)(3N)(RISE? OR RISING? OR ELEVAT? OR HIGH? OR INCREAS?)

S4

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S5

GD()EOB()DTPA+GADOXETIC?(3W)ENHANCE?(3W)(MRI OR MR)

S6

CONTRAST?(3W)(CT OR MR OR NMR OR MRI OR ULTRASON?)

S7

CTAP OR CTHA OR IODI?(3N)CONTRAST? OR GD OR GADOXETIC? OR DTPA OR EOB OR SONAZOID?

S8

CONTRAST?(3W)ENHANC? OR ENHANC?(3N)(CT OR MR OR NMR OR MRI OR ULTRASON?)

S9

(DI+DIAGNOSIS!+RA+RI+US)/DF

S10

(S1+S2+S3+S4)*S5/TI

S11

(S1+S2+S3)*S4*(S5+S6+S7+S8)/TI

S12

(HEPATIC? OR HEPATO? OR LIVER? OR S1+S2+S3)/TI AND S11

S13

S12*S9

S14

S13+S10

S15

S14/HUMAN+(S14 NOT ANIMALS)

S16

S15 AND PY=>1982 AND UP=19830906:20111231

S17

S16/ENG

S18

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S19

S17 NOT S18

S20

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S21

S17*S20

S22

S19+S21

CQ15 肝細胞癌の画像診断において,どのように造影剤を用いるべきか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER―ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?

S6

ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF

S7

CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE)(1N)(MEDIA?+DYE?+MATERIAL?+AGENT?)

S8

SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC

S9

S4*(S5+S6)*S7

S10

S8*S9

S11

(CONTRAST? OR IODINE? OR GD)/TI AND S9

S12

S10+S11

CQ16

肝細胞癌の病期診断に頭部MRI,胸部CT,骨シンチグラフィー,FDG―PETは必要か?
[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:20111231

S5

DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER―ASSISTED!+TOMOGRAPH?+IMAG?+ANGIOGRAPHY!+ARTERIOGRAPH?+ANGIOGRAPH?+AORTOGRAP?+CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+ULTRASONOGRAPHY!+ULTRASON?

S6

ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF+NUCLEAR(1W)MEDICINE(2N)DIAGNOSIS?+NUCLEAR MEDICINE!*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+(RA+RI)/DF

S7

STAGE? OR STAGING? OR METASTA? OR INFILTRA? OR INVASI? OR INVOLVE?

S8

S4*(S5+S6)*S7

S9

CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING? OR DETECT? OR DIAGNOS?

S10

S8*(S7/TI+S9/TI)*(HEPATO? OR HEPATIC? OR LIVER?)/TI

S11

S10*(S7/TI+DETECT?/TI+DIAGNO?/TI)

S12

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S13

S11 NOT S12

S14

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S15

S11*S14

S16

S15+S13

CQ17 造影超音波は,肝細胞癌における診断能を改善するか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF

S18

CONTRAST MEDIA!+(CONTRAST+RADIOPAQUE)(1N)(MEDIA?+DYE?+MATERIAL?+AGENT?)/TI

S19

(DI OR DIAGNOSIS! OR RA OR RI OR US)/DF OR DIAGNOS?/TI

S20

S16*S17*S18*S19

S21

S20*S19/MAJ

S22

S21*S17/MAJ

CQ18 造影超音波は,局所療法やTACEの治療効果判定に有用か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DF

S2

(CLINICAL+CRITICAL+TREATMENT?+CARE)(2N)(PATH+PATHS+PATHWAY?+PROTOCOL?+PLANNING?+GOOD(2W)PRACTICE?)/TI

S3

(SYSTEMATIC+QUANTITATIVE+METHODOLOGIC+COLLABORATIVE+INTEGRATIVE)(1W)(REVIEW?+OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DF+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DF+RANDOM ALLOCATION/DF+RANDOM?+DOUBLE―BLIND METHOD/DF+SINGLE―BLIND METHOD/DF+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DF+SINGLE―BLIND METHOD/DF+CROSS―OVER STUDIES/DF+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/ID+CONTROL?(1W)(TRIAL?+STUD?)+PLACEBO?/TI

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!+(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+COHORT?/TI

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DF+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DF+CASE()(CONTROL+COMPARISON?+REFERENT?+REFERRENT?)/TI+RETROSPECTIVE?/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

ULTRASONOGRAPHY!+ULTRASON?+ECHOGRAPH?+ECHO? ?+SONOGR?+ULTRASOUND?+ULTRASONICS!+US/DF

S18

(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANS)(W)(CATHETER?+ARTER???))(3N)(EMBOLI?+CHEMOEMBOLI?)

S19

(LOCAL+TOPICAL)(3N)(REMED?+THERAP?+TREATMENT?)

S20

(BENEFIT?+EFFECT?+EFFIC?+GAIN?+PERFORMANCE?+ACTION?)(1N)(TREATMENT?+THERAP?+CURATIVE?)

S21

S16*S17*(S18+S19)*S20

S22

S16*S17*(S18+S19)

S23

S15*S17*(S18+S19)*S20

【第3章 手 術】

CQ19

肝切除術を行う際の術前肝機能評価因子は何を用いるのが適当か?
また肝機能面からみた手術適応は?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3*UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

(HCC+LIVER+HEPAT?+NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)

S11

HEPATECTOM?

S12

S9 AND(S10 OR S11)

S13

PREOPERAT?+PRESURGER?+(BEFORE+PRE+PRIOR)(W)(OPERAT?+SURGER?)

S14

PREDICT?/DE AND SURGERY/DE

S15

S13+S14

S16

S15(3N)(ASSESSMENT? OR TEST? ?)

S17

S15 AND(HEPAT? OR LIVER)(3N)(FUNCTION? OR STATUS?)

S18

S12 AND(S16 OR S17)

CQ20 標準的な肝切除術式とは?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:20111231

S5

LIVER NEOPLASMS!(L)SU

S6

HEPATECTOMY!

S7

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

S8

(NEW? OR STANDARD? OR GOLDSTANDARD? OR APPROACH? OR METHOD? OR TECHNI?)/TI

S9

HEPATECTOMY!(L)METHODS

S10

(S5+S6)*S7*S8

S11

(SEGMENT? OR SUBSEGMENT?)/TI*(S5+S6)*S8

S12

S4*(S9+S10+S11)

CQ21 腫瘍条件からみた肝切除の適応は?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

HEPATECTOMY!

S16

LIVER NEOPLASMS(L)SU

S17

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

S18

(INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)

S19

(EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)

S20

INDICAT?/TI+INDICAT?(3N)(SURGER?+SURGIC?+RESECT?+OPERAT?+HEPATECTOM?)

S21

S14*(S15+S16+17)*(S18+S19+S20)

S22

S21*UP=20070701:20111231

CQ22 肝切除後の予後因子は何か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIVE?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

(HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)

S18

HEPATECTOM?

S19

S16 AND(S17 OR S18)

S20

(PREDICT? OR PROGNOS?)(N)(FACTOR? OR VARIABL?)

S21

S19 AND S20

S22

S21 AND(CARCINOMA, HEPATOCELLULAR!)/MAJ

CQ23 切除断端距離は予後に寄与するか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

(HCC+LIVER+HEPAT?)(3N)(RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)

S18

HEPATECTOM?

S19

S16 AND(S17 OR S18)

S20

SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION? OR MARGIN?

S21

PROGNOSIS!+PROGNOS?+(TREATMENT?+LATE?+LONG(1W)TERM)(2N)(CONSEQUENCE?+OUTCOME?+RESULT?)+SURVIVAL(1W)RATE?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S22

S19 AND S20 AND S21

S23

S22 AND(CARCINOMA, HEPATOCELLULAR!)/MAJ

CQ24 系統的切除は予後に寄与するか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

(ANATOMI?+SYSTEMIC?+SYSTEMATIC?)(4N)(RESECT?+HEPATECTOM?+SURGER?+SURGICA?+OPERATI?)

S18

PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S19

S16*S17*S18

CQ25 周術期の血液製剤の積極的な投与は推奨されるか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S12 NOT ANIMALS)

S3

S2/ENG

S4

S3*UP=20070701:20111231

S5

SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S6

PERIOPERAT?+INTRAOPERAT?+(PERI+INTRA+DURING?)(3N)(OP+SURGER???+OPERAT?+HEPATECTOM?+RESECT?)

S7

BLOOD TRANSFUSION! OR(BLOOD? OR ERYTHROCY? OR RED()CELL? ? OR PLASMA?)(3N)TRANSFUS? OR FROZEN?(3N)PLASMA?

S8

BLOOD()(DERIVATIVE?+PREPARATION?+PRODUCT?+FORMUL?)+(HEMATOLOGIC?+HEMOPOIETIC?+HEMATOPOIETIC?)(2W)(DRUG? ?+AGENT? ?+FORMUL?)

S9

S4*S5*S6*(S7+S8)

CQ26 肝流入血流遮断や中心静脈圧低下は,肝切離中出血量を減少させるか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPRCTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

S11/HUMAN+(S11 NOT ANIMALS)

S13

S12/ENG

S14

S13*UP=20070701:20111231

S15

SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S16

BLOOD LOSS, SURGICAL!+BLOOD()LOSS?+(HEMORRHAGE?+BLEED?+HAEMORRHAG?)(3N)(OP+SURGIC?+SURGER???+OPERAT?+HEPATECTOM?+RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S17

S14*S15*S16

S18

PEDICL?(1W)(CLAMP?+OCCLUS?)+IPO+HPC+PRINGL?

S19

((CENTRAL?(1W)VENOUS?(1W)PRESSUR?)+CVP)(3N)(REDUC?+LOW+DECREAS?+FALL??+DROP???)

S20

S17*(S18+S19)

S21

PEDICL?(1W)(CLAMP?+OCCLUS?)+IPO+HPC+PRINGL?+PORTAL()TRIAD()CLAMP?+PTC

S22

S17*(S19+S21)

CQ27 肝切除において腹腔ドレーン留置は必要か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+WSCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

S11/HUMAN+(S12 NOT ANIMALS)

S13

S12/ENG

S14

S13 AND PY=>1982 AND UP=19830906:20111231

S15

SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S16

ABDOM?(2N)DRAIN?

S17

S14*S15*S16

CQ28 術前補助化学療法は肝切除後の予後を改善するか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S18

NEOADJUVANT?+NAC+NEO()ADJUVAN?

S19

(PREOPERAT?+(BEFORE+PRE)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOEMB?+EMBOL?+CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)

S20

(CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!)*(PREOPERAT?+(BEFORE+PRE)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))

S21

S16*S17*(S18+S19+S20)

S22

PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S23

S21*S22

CQ29 術後補助化学療法は肝切除後の予後を改善するか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+RETROSPECTIV STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14*UP=20070701:20111231

S16

S11*S15

S17

SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?)(3N)(RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S18

CHEMOTHERAPY, ADJUVANT!+ADJUVANT?(3N)CHEMOTHER?

S19

(POSTOPERAT?+(AFTER+FOLLOW?)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))(4N)(CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)

S20

(CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!)*(POSTOPERAT?+(AFTER+FOLLOW?)(3N)(SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))

S21

S16*S17*(S18+S19+S20)

S22

PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S23

S21*S22

CQ30 肝移植前のダウンステージングは肝移植の予後を改善するか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

LIVER TRANSPLANTATION! OR LIVER!(L)TR OR TRANSPLAN?

S11

DOWN?()STAG? OR DOWNSTAG?

S12

S9*S10*S11

S13

PRE()TRANSPLAN? OR PRETRANSPLAN? OR TRANSPLAN?(3N)(BEFOR? OR FOLLOW? OR AFTER? OR WAIT?)

S14

BRIDGING? OR ABLAT? OR RFA

S15

(LOCAL?+LOCOREGION?+LOCO()REGION?+TOPICAL? OR BRIDG?)(3N)(THERAP?+TREAT?)

S16

TAE OR TACE OR(TRANSCATHETER? OR TRANSARTER?)(3N)(EMBOLI? OR CHEMOEMBOLI?)

S17

S13(5N)(S14+S15+S16)

S18

S9*S17

S19

S12+S18

CQ31 肝細胞癌に対する肝移植の適応基準は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

LIVER TRANSPLANTATION! OR LIVER!(L)TR OR TRANSPLAN?

S11

LIVER TRANSPLANTATION!(L)UT OR TRANSPLANT?(3N)UTILIZ?

S12

(INDICAT?+ADAPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?+ELIGIBL?+CANDIDAT?+OFFER?)(4N)TRANSPLANT?

S13

CRITERI?(4N)S12

S14

S9*S11

S15

S9*S13

S16

S9*S12

S17

S9*TRANSPLAN?/TI*(CRITERI?+PRIORIT?)

S18

S14+S15+S16+S17

【第4章 穿刺局所療法】
CQ32 穿刺局所療法はどのような患者に行うべきか?[PubMed]

CQ33 各穿刺局所療法の選択は,どのように行うべきか?[PubMed]

CQ34 穿刺局所療法にTACEを併用することで予後を改善できるか?[PubMed]

CQ35 造影超音波,CTやMRIとのfusion imageは局所治療の治療ガイドとして有用か?[PubMed]

#1

(“carcinoma, hepatocellular”[MH]OR“HCC”[tiab])AND(“Ethanol Injection”[tiab]OR“Ablation”[tiab]OR“Ablative”[tiab]OR“Thermal Ablation”[tiab]OR“radiofrequency”[tiab]OR“RFA”[tiab]OR“RFTA”OR“PEI”[tiab]OR“PEIT”[tiab]OR“Ethanol/administration and dosage”[MH]OR“Injections, Intralesional”[MH]OR“microwave”[tiab])AND 2007/7/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

(“carcinoma, hepatocellular”[MH]OR“HCC”[tiab])AND(“Ethanol Injection”[tiab]OR“Ablation”[tiab]OR“Ablative”[tiab]OR“Thermal Ablation”[tiab]OR“radiofrequency”[tiab]OR“RFA”[tiab]OR“RFTA”OR“PEI”[tiab]OR“PEIT”[tiab]OR“Ethanol/administration and dosage”[MH]OR“Injections, Intralesional”[MH]OR“microwave”[tiab])AND 2007/7/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

CQ36 局所療法の効果判定に有用な画像診断は何か?[PubMed]

#1

(“carcinoma, hepatocellular”[MH]OR“HCC”[tiab])AND(“Ethanol Injection”[tiab]OR“Ablation”[tiab]OR“Ablative”[tiab]OR“Thermal Ablation”[tiab]OR“radiofrequency”[tiab]OR“RFA”[tiab]OR“RFTA”OR“PEI”[tiab]OR“PEIT”[tiab]OR“Ethanol/administration and dosage”[MH]OR“Injections, Intralesional”[MH]OR“microwave”[tiab])AND(“MRI”[tiab]OR“CT”[tiab]OR ultraso*[tiab])1982/1/1:2011/11/15[dp]AND Eng[la]NOT“case reports”[pt]

#2

(“carcinoma, hepatocellular”[MH]OR“HCC”[tiab])AND(“Ethanol Injection”[tiab]OR“Ablation”[tiab]OR“Ablative”[tiab]OR“Thermal Ablation”[tiab]OR“radiofrequency”[tiab]OR“RFA”[tiab]OR“RFTA”OR“PEI”[tiab]OR“PEIT”[tiab]OR“Ethanol/administration and dosage”[MH]OR“Injections, Intralesional”[MH]OR“microwave”[tiab])AND(“MRI”[tiab]OR“CT”[tiab]OR ultraso*[tiab])1982/1/1:2011/12/31[dp]AND 2011/11/16:2012/3/30[MHDA]AND Eng[la]NOT“case reports”[pt]

#3

#1 or #2

【第5章 肝動脈化学塞栓療法(TACE)】
CQ37 どのような症例がTACE/TAEのよい適応か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+EMBOLIZE?+(EMBOL?+THROMBUS?)(1N)FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE+((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?)

S11

(INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)

S12

(EFFECTIV?+BENEFIT?)(3N)(PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)

S13

INDICAT?/TI+INDICAT?(3N)(ETHANOL?+RFA+PEI+PMCT+ABLAT?)

S14

S9*S10*(S11:S13)

CQ38 TACE/TAEにおいて塞栓物質や抗癌剤は何を用いるべきか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE

S11

((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)

S12

CHEMOEMBOLIZATION, THERAPEUTIC!

S13

S9*(S10+S11+S12)

S14

AD/DE+TU/DE

S15

ANTINEOPLASTIC AGENTS!(L)(TU+AD)

S16

S13*(S14+S15)

S17

TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI?

S18

SUSPENS? OR MICROSPHE? OR OIL? ? OR CARRIER? OR BEAD? ? OR MATERIAL? OR AGENT? ? OR DRUG? ? OR COMPOUND? ? OR EMULS?

S19

S9*S17/TI*S18/TI

S20

S17/TI*S16

S21

S20*S18/DE

S22

S19+S21

CQ39 再TACE/TAEの時期の選択は?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

S4 NOT S5

S7

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8

S4*S7

S9

S6+S8

S10

(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE

S11

((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)

S12

CHEMOEMBOLIZATION, THERAPEUTIC! OR CHEMOTHERAPY, ADJUVANT!

S13

S9*(S10+S11+S12)

S14

RETRI?+RE()TRI???+RETRY?+RE()TRY?+TRY()AGAIN?+REPERFORM?+RE()PERFORM?

S15

ANOTHER?+REPEAT?+ADDITION?+SUPPLEMENT?+TWICE?+TWO()TIMES?+RETREATMENT?+RE()TREATMENT?+AGAIN?

S16

SECOND? OR 2ND

S17

RETHERAP? OR REAPPROACH? OR RE()(THERAP? OR APPROACH?)

S18

REEMBOLI? OR RECHEMOEMBOLI? OR RETRANSCATHE? OR RETRANSARTER?

S19

RETACE? OR RETAE OR RETRANSANTITHROMBO?

S20

RE()(TACE OR TAE OR ANTITHROMBO? OR ANTI()THROMBO?)OR REANTITHROMBO?

S21

S13*(S14+S15+S16+S17+S18)/TI

S22

TIME? OR TIMING? OR PERIOD? OR INTERVAL? OR OCCASION? OR POINT?

S23

S13*S18

S24

S13*(S14+S15+S16+S17+S18)

S25

S24*S22

S26

(S14+S15+S16+S17)(4N)(TACE OR TAE OR TRANSCATHE? OR TRANSARTE? OR EMBOLI? OR CHEMOEMBOLI? OR TREAT? OR THERAP?)

S27

S26*S24

S28

TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI? OR TAE OR TACE

S29

(S27+S25)*S28/TI

S30

S29+S21

CQ40 TACEの効果判定に有用な画像診断は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

(ANTITHROMBOTIC+ANTI(1W)THROMBOTIC)(1W)REGIMEN?+TAE+TACE

S16

((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS)(W)(CATHETER?+ARTER???+ARTERIAL?))(3N)(EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)

S17

CHEMOEMBOLIZATION, THERAPEUTIC!

S18

S14*(S15+S16+S17)

S19

(S15 OR CHEMOEMBOLI? OR CHEMOINFU? OR LOCOREGIONAL?()THERAP?)/TI

S20

RA/DF OR US/DF OR RI/DF OR DIAGNOSTIC IMAGING! OR LIVER NEOPLASMS!(L)PA

S21

((TUMOR OR TUMOUR)()RESPONSE? OR INDICATOR? OR VISUALIZ? OR ASSESS? OR EVALUAT? OR THERAPEUTIC()EFFECT? OR IMAGING? OR FEATURE? OR FINDING? OR CT OR MR OR MRI)/TI

S22

(USEFUL? OR EFFECTIVE? OR EFFICAC? OR BENEFIT?)/TI

S23

S18*S19*S20

S24

S23*(S21+S22)

【第6章 化学療法】
CQ41 全身化学療法はどのような症例に行われるか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14 AND UP=20070701:20111231

S16

S11*S15

S17

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S18

S16*S17

S19

S17/TI AND S18

S20

DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS!(L)(TU+AD)

S21

S18*S20

S22

S20/MAJ AND S21

S23

S22+S19

S24

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S25

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S26

S23 NOT S24

S27

S23*S25

S28

S26+S27

CQ42 肝動注化学療法は予後を改善するか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

DT=META―ANALYSIS or(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S7

S4 NOT S5

S8

S4*S6

S9

S7+S8

S10

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S11

S9*S10

S12

HAI+(INTRAARTER?+ARTER?)(3N)(ADMINISTR?+DOSE?+DOSING?+INFUS?+INJECT?)

S13

(INTRAARTER? OR ARTER?)(3N)(THERAP? OR CHEMOTHERAP? OR TREAT?)

S14

PROGNOSIS!+PROGNOS?+OUTCOME?+SURVIV?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S15

S11*(S12+13)*S14

CQ43 化学療法(薬物療法)で有効な治療は何か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S12/HUMAN+(S12 NOT ANIMALS)

S14

S13/ENG

S15

S14 AND UP=20070701:20111231

S16

S11*S15

S17

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S18

DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS!(L)(TU+AD)

S19

S16*(S17/TI+S18/MAJ)

S20

S19*S12/TI

S21

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S22

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S23

S20 NOT S21

S24

S20*S22

S25

S23+S24

CQ44 ホルモン療法は有効か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S7

S4 NOT S5

S8

S4*S6

S9

S7+S8

S10

GONADOTROPIN―RELEASING HORMONE!+(LUTEINI?+GONADOTROPIN?)(3N)RELEAS?(2N)HORMON?(2N)(AGONIST?+ANALOG?)+LH(1W)RH+LHRH+GONADORELIN?+(GNRH+LHRH+(GN+LH)(1W)RH)(W)(AGONIST?+ANALOGUE?)+BUSERELIN?+GOSERELIN?+LEUPROLI?+NAFARELIN?+TRIPTORELIN?

S11

AROMATASE INHIBITORS!+AROMATAS?(2N)INHIBIT?+AMINOGLUTETHIMID?+TESTOLACTON?+FADROZOL?+ANASTROZOL?+LETROZOL?+EXEMESTAN?

S12

TAMOXIFEN?+ADOPAN+EMALOOK+SOSHIGEN+TASUOMIN+NORXIFEN+NOLVADEX+PANLEEF+PHENOLURN+RESPOL+ICI(1W)46474+ICI46474+ICI(1W)47699+ICI47699+ZITAZONIUM

S13

S10:S12

S14

S S9*S13

CQ45 化学療法(薬物療法)の治療効果予測因子・予後因子は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND UP=20070701:20111231

S5

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S6

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S7

S4 NOT S5

S8

S4*S6

S9

S7+S8

S10

(PROGNOS?+PREDICT?)(1W)(FACTOR?+VARIABLE?+INDEX+INDIC?)+PREDICTOR?

S11

S9*S10

S12

(BENEFIT?+EFFECT?+EFFIC?+GAIN?+PERFORMANCE?+ACTION?+RESPON?+OUTCOM?)(3N)(CHEMOTHER?+CHEMORADIOTHER?+TREATMENT?+THERAP?+CURATIVE?)

S13

S11*S12

S14

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S15

S13*S14

CQ46 化学療法の治療効果判定はどのようにするか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S12

S9 NOT S10

S13

S9*S11

S14

S12+S13

S15

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S16

RESPON?(2N)(CRITERIA?+EVALUAT?)

S17

S14*S15*S16

CQ47 化学療法の副作用とその対策は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S11

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S12

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S13

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S14

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S15

DT=META―ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S16

S9 NOT S14

S17

S9*S15

S18

S16+S17

S19

DRUG THERAPY!+DT/DF+RADIOCHEM?+CHEMORADIO?+CHEMOTHERAP?+ANTINEOPLASTIC AGENTS!(L)(TU+AD)+CYCLOPHOSPHAMIDE?+FLUOROURACIL?+5(1W)FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S20

ANTINEOPLASTIC AGENTS!(L)(AE+PO+CT+TO)

S21

(ADVERS?+SAFETY+TOXIC?)/TI

S22

(ADVERS?+SAFETY+TOXIC?)(2N)(MANAG?+PROPHYLAX?+PREVEN?)

S23

S18*S19

S24

S23*S21+S23*S22*S20+S20*(S10:S13)*S23

【第7章 放射線治療】
CQ48 肝細胞癌に対する,3次元原体照射法による放射線治療は有用か?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S11*S12

S14

S13/HUMAN OR(S13 NOT ANIMALS)

S15

S14/ENG

S16

S15 AND UP=20070701:20111231

S17

RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S18

S16*S17

S19

PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S20

EFFECACY OR SURVIVAL? OR RESPONSE()(RATE OR RATES)OR LOCAL()CONTROL? OR SAFETY OR ADVERS?(1W)(EFFECT? OR EVENT OR EVENTS)OR TOXICITY OR FEASIBILITY

S21

S19+S20

S22

S18*S21

CQ49 肝細胞癌に対する,体幹部定位放射線治療は有用か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

STEREOTACTIC(3N)(RADIOTHERAP? OR RADIOSURG? OR RADIATION? OR IRRADIAT?)

S3

RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S4

SBRT OR SBT OR SRT OR STEREOTACTIC OR PINPOINT?

S5

DT=REVIEW?

S6

S1 NOT S5

S7

S6/HUMAN+(S6 NOT ANIMALS)

S8

S7/ENG

S9

S8 AND PY=>1982 AND UP=19830906:19900630

S10

S8 AND PY=>1982 AND UP=19900630:19950630

S11

S8 AND PY=>1982 AND UP=19950630:20000630

S12

S8 AND PY=>1982 AND UP=20000630:20050630

S13

S8 AND PY=>1982 AND UP=20050630:20111231

S14

S9:S13

S15

S14*S2

S16

S14*S3*S4

S17

S15+S16

CQ50

肝細胞癌に対する,粒子線治療〔陽子線治療,重粒子(炭素イオン)線治療〕は有用か?
[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

(HEAVY OR CARBON? OR PROTON? OR PARTICL?)(2N)(THERAP? OR ION OR IONS OR BEAM OR BEAMS OR IRRADIAT? OR RADIOISOTOP?)

S3

RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S4

DT=REVIEW?

S5

S1 NOT S4

S6

S5/HUMAN+(S5 NOT ANIMALS)

S7

S6/ENG

S8

S7 AND PY=>1982 AND UP=19830906:19900630

S9

S7 AND PY=>1982 AND UP=19900630:19950630

S10

S7 AND PY=>1982 AND UP=19950630:20000630

S11

S7 AND PY=>1982 AND UP=20000630:20050630

S12

S7 AND PY=>1982 AND UP=20050630:20111231

S13

S8:S12

S14

S13*S2*S3

CQ51 肝細胞癌の遠隔転移に対しては,放射線治療が適応となるか?[MEDLINE]

S1

DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE―BASED MEDICINE/DE

S2

(CLINICAL+CRITICAL)(1W)(PATH+PATHS+PATHWAY?)/TI+(CLINICAL+TREATMENT?)(2N)PROTOCOL?/TI+CARE(1N)PLANNING?/TI+(GOOD(1W)CLINICAL(1W)PRACTICE?)/TI

S3

(SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE)(1W)(REVIEW? OR OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)

S4

DT=META―ANALYSIS+META―ANALYSIS/DE+(META()ANALY?+METAANAL?)/TI

S5

DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE―BLIND METHOD/DE+SINGLE―BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?)(W)(BLIND?+MASK?)

S6

DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE―BLIND METHOD/DE+CROSS―OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL?(1W)(TRIAL?+STUD?)

S7

DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE)(2W)(TRIAL?+STUDY+STUDIES)/TI

S8

COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS()SECTION?+COHORT?+FOLLOW()UP+FOLLOWUP)(1W)(STUDY+STUDIES)/TI+EPIDEMIOLOGIC STUDIES!

S9

DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI(W)CENT?)/TI

S10

CASE―CONTROL STUDIES!+MATCHED―PAIR ANALYSIS/DE+CASE()CONTROL/TI

S11

S1:S10

S12

CARCINOMA, HEPATOCELLULAR!+(HEPATOCELL?+HAEPATOCELL?+(HEPATO+HAEPATO))(W)(CELL??+CELLULA?)(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S13

S11*S12

S14

S13/HUMAN OR(S13 NOT ANIMALS)

S15

S14/ENG

S16

S15 AND UP=20070701:20111231

S17

RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S18

S16*S17

S19

PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S20

EFFECACY OR SURVIVAL? OR RESPONSE()(RATE OR RATES)OR LOCAL()CONTROL? OR SAFETY OR ADVERS?(1W)(EFFECT? OR EVENT OR EVENTS)OR TOXICITY OR FEASIBILITY

S21

S19+S20

S22

S18*S21

S23

S1:S6

S24

S23/HUMAN OR(S23 NOT ANIMALS)

S25

S24/ENG

S26

S25 AND UP=20070701:20111231

S27

(RADIOTHERAPY!+RT/DF+RADIOCHEM?+CHEMORADIO?+IRRADIAT?+RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?)*METASTA?

S28

S16*S27

S29

S26*S27

S30

METASTA?(4N)(RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT?+BRACHYTHER?+RADIOSURG?)

S31

S16*S30

S32

S26*S30

S33

CENTRAL NERVOUS SYSTEM NEOPLASMS!(L)SECONDARY OR BONE NEOPLASMS!(L)SECONDARY

S34

(BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?)(4N)METASTA?

S35

S28+S31

S36

(S29+S32)*(S33+S34)

S37

(BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?)/TI AND S36

S38

S35+S37

S39

S34/TI AND S36

S40

S39+S35

【第8章 治療後のサーベイラインス,再発予防,再発治療】

CQ52

肝切除後や穿刺局所療法後,どのようにフォローアップするか?
(1)肝切除後,どのようにフォローアップするか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

HEPATECTOMY!

S16

LIVER NEOPLASMS(L)SU

S17

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

S18

FOLLOWUP OR FOLLOW()UP

S19

S14*(S15+S16+S17)

S20

S18*S19

S21

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)(4N)(AFTER OR FOLLOW?)

S22

POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST()(SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)

S23

S18/TI*S19

S24

S18(3N)(EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)

S25

(S21+S22)(4N)S18

S26

S20*S24

S27

S20*S25

S28

(S26+S27)*(S21+S22)/TI+S23

CQ52

肝切除後や穿刺局所療法後,どのようにフォローアップするか?
(2)穿刺局所療法後,どのようにフォローアップするか?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

(PEI OR PEIT OR EIT)AND ETHANOL??

S16

MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)

S17

(PMCT OR MCT)AND MICROWAVE?

S18

ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?

S19

RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA

S20

PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)

S21

PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?

S22

RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?

S23

(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)

S24

S15:S23

S25

S14*S24

S26

FOLLOWUP OR FOLLOW()UP

S27

S25*S26

S28

S26/TI*S27

S29

S26(3N)(EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)

S30

(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)(4N)S26

S31

S29*S27

S32

S30*S27

S33

S28+S31+S32

S34

POST()(RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)

S35

S33*(S34+S24/TI)

CQ53

肝切除後や穿刺局所療法後の有効な再発予防法は何か?
(1)肝切除後の有効な再発予防法は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

HEPATECTOMY!

S16

LIVER NEOPLASMS(L)SU

S17

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

S18

RECURREN?

S19

NEOPLASM RECURRENCE, LOCAL!(L)PC

S20

(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)

S21

S14*(S15+S16+S17)*S18

S22

S21*(S19+S20)

S23

(S18/TI+S17)AND S22

S24

(PREVEN? OR PROPHYL? OR REDUC? OR DECREAS?)/TI AND S22

S25

S23+S24

CQ53

肝切除後や穿刺局所療法後の有効な再発予防法は何か?
(2)穿刺局所療法後の有効な再発予防法は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

(PEI OR PEIT OR EIT)AND ETHANOL??

S16

MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)

S17

(PMCT OR MCT)AND MICROWAVE?

S18

ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?

S19

RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA

S20

PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)

S21

PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?

S22

RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?

S23

(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)

S24

S15:S23

S25

RECURREN?

S26

NEOPLASM RECURRENCE, LOCAL!(L)PC

S27

(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)

S28

S14*S24*S25

S29

S28*(S26+S27)

S30

SURVIV?(3N)(INCREAS? OR PROLONG? OR IMPROV?)

S31

(PREDICT? OR DETECT?)(3N)(PROGRES? OR RECURREN?)

S32

USEFUL? OR EFFECTIVE? OR EFFICAC?

S33

S28*S30

S34

S28*S31

S35

TREATMENT OUTCOME/DE

S36

(S33+S34)*(S32+S35)

S37

S36*(S24/TI OR S25/TI OR PROVEN? OR PROPHYL? OR REDUC? OR S30/TI)

S38

S29+S37

S39

(S24/TI OR MT/DE OR TU/DE OR S24/MAJ)AND S38

CQ54 肝移植後の有効な再発予防法は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

LIVER TRANSPLANTATION! OR LIVER!(L)TR OR LIVER?(3N)TRANSPLANT?

S16

RECURREN?

S17

NEOPLASM RECURRENCE, LOCAL(L)PC

S18

(PROGRES? OR RECURREN?)(3N)(PREVEN? OR PROPHYLA?)

S19

IMMUNOSUPPRESSIVE AGENTS!(L)TU

S20

SURVIV?(3N)(INCREAS? OR PROLONG? OR IMPROV?)

S21

(PREDICT? OR DETECT?)(3N)(PROGRES? OR RECURREN?)

S22

USEFUL? OR EFFECTIVE? OR EFFICAC?

S23

TREATMENT OUTCOME/DE

S24

S14*S15*S16

S25

S24*(S17+S18)

S26

S24*(S19+S20+S21)

S27

S26*(S22+S23+S20/TI)

S28

S25+S27

S29

LIVER TRANSPLANTATION!/MAJ OR LIVER TRANSPLANTATION!(L)MT OR TRANSPLANT?/TI

S30

S29*S28

CQ55 肝切除後の再発に対する有効な治療は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

HEPATECTOMY!

S16

LIVER NEOPLASMS(L)SU

S17

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)/TI

S18

(HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?)(4N)(AFTER OR FOLLOW?)

S19

POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST()(SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)

S20

(S18+S19)(4N)RECURREN?

S21

S14*(S15+S16+S17)

S22

S20*S21

S23

NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)

S24

S22*S23

S25

S20/TI*S22

S26

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI

S27

S26 AND S25

S28

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(5N)S20

S29

S25*S28

S30

RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!

S31

TU/DE

S32

S25*S30*S31

S33

S24*S20/TI

S34

S24+S27+S29+S32+S33

CQ56 穿刺局所療法後の再発に対する有効な治療法は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

(PEI OR PEIT OR EIT)AND ETHANOL??

S16

MICROWAVES/DE OR MICROWAVE?(3N)(PERCUTAN? OR COAGULAT?)

S17

(PMCT OR MCT)AND MICROWAVE?

S18

ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?

S19

RADIOFREQUEN? OR RADIO()FREQUEN? OR RFA

S20

PEI*(PERCUTANEOUS?+ETHANOL?)+PEIT+(PERCUTANEOUS?+TRANSDERMAL?)(2N)(ETHANOL? OR ETHYL()ALCOHOL?)

S21

PMCT+PERCUTANEOUS?(1W)COAGULAT?(1W)THERAP?

S22

RFA+(RADIO(1W)(FREQUENC?+WAVE?)+RADIOFREQUEN?)(2N)ABLAT?

S23

(LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO()REGIONAL?)(3N)(REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)

S24

S15:S23

S25

S14*S24

S26

(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)(4N)(AFTER OR FOLLOW?)

S27

POST()(RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)

S28

(S26+S27)(4N)RECURREN?

S29

NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)

S30

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI

S31

S25*S28

S32

S29*S31

S33

S30*S31

S34

RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!

S35

TU/DE

S36

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(4N)S28

S37

S31*S36

S38

S31*S34*S35

S39

(AFTER OR FOLLOW?)(1W)(PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?)

S40

RECURREN?(3W)S39

S41

S40*S31*(S29+S30)

S42

S32+S33+S37+S38+S41

CQ57 肝移植後の再発に対する有効な治療法は何か?[MEDLINE]

S1

CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+HAEPATO?+LIVER?)(W)(CELL??+CELLULA?))(2N)(NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+(HEPATOMA? ?+HAEPATOMA? ?)/TI+(HCC+HCCS)/TI*LIVER NEOPLASMS!

S2

S1/HUMAN+(S1 NOT ANIMALS)

S3

S2/ENG

S4

S3 AND PY=>1982 AND UP=19830906:19900630

S5

S3 AND PY=>1982 AND UP=19900630:19950630

S6

S3 AND PY=>1982 AND UP=19950630:20000630

S7

S3 AND PY=>1982 AND UP=20000630:20050630

S8

S3 AND PY=>1982 AND UP=20050630:20111231

S9

S4:S8

S10

DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE()REPORT?/TI

S11

S9 NOT S10

S12

DT=META―ANALYSIS OR META ANALYSIS OR(META(1W)ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC(1W)REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13

S9*S12

S14

S11+S13

S15

LIVER TRANSPLANTATION! OR LIVER!(L)TR OR LIVER?(3N)TRANSPLANT?

S16

S14*S15

S17

NEOPLASM RECURRENCE, LOCAL!(L)(TH+DT+RT+SU)

S18

RECURREN?(4N)((FOLLOW? OR AFTER)(4N)TRANSPLAN? OR POSTTRANSPLAN? OR POST()TRANSPLAN?)

S19

S16*S17

S20

S16*S18/TI

S21

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)/TI

S22

S20 AND S21

S23

(TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?)(5N)S18

S24

S23*S16

S25

RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!

S26

TU/DE

S27

S16*S25*S26

S28

S19+S22+S24+S27